Shares of Veracyte Inc. (VCYT) reached a 52-week high of $42.99 during intraday yesterday, reflecting investor optimism surrounding the company's ongoing developments.
Veracyte, a molecular diagnostics company that uses genomic technology to resolve diagnostic ambiguity, recently reported strong third-quarter results and raised its 2024 revenue outlook.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com